Centessa Pharmaceuticals (NASDAQ:CNTA) Issues Earnings Results, Beats Estimates By $0.04 EPS

Centessa Pharmaceuticals (NASDAQ:CNTA) released its quarterly earnings data on Monday. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.04, Zacks reports.

Centessa Pharmaceuticals Stock Up 5.6 %

Shares of NASDAQ:CNTA opened at $16.63 on Tuesday. The firm has a market capitalization of $2.19 billion, a PE ratio of -10.87 and a beta of 1.54. Centessa Pharmaceuticals has a 1 year low of $7.75 and a 1 year high of $19.09. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The firm’s 50-day moving average is $16.49 and its two-hundred day moving average is $16.42.

Insider Activity

In related news, insider Gregory M. Weinhoff sold 10,000 shares of the business’s stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $17.04, for a total transaction of $170,400.00. Following the completion of the transaction, the insider now directly owns 183,266 shares of the company’s stock, valued at $3,122,852.64. The trade was a 5.17 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $15.29, for a total value of $91,740.00. Following the completion of the sale, the general counsel now directly owns 118,265 shares in the company, valued at $1,808,271.85. This represents a 4.83 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 260,168 shares of company stock valued at $4,316,568. 11.59% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Morgan Stanley reissued an “overweight” rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Guggenheim reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. Finally, TD Cowen assumed coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $26.00.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.